Tatiana Doldonova, winner of the Experienced CRA category in last year's PharmaTimes Clinical Researcher of the Year - The Americas competition, reflects on her role in clinical research and what it means to win a Pharma.
A group of doctors is calling on health secretary Matt Hancock to stream some of the recently announced £75 million funding for prostate cancer into greater provision of a new method for diagnosing the condition.
Germany's Merck and GlaxoSmithKline have announced a global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult to treat cancers, in a deal worth up to 3.7 billion euros.
Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla to include the adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
AstraZeneca’s MEDI8897 has been granted access to both the European Medicines Agency (EMA) PRIME (PRIority MEdicines) scheme, and the US Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD).
A Phase III trial of Sanofi's isatuximab’s has proven successful, showing that the drug achieved the primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other cancer types.
AstraZeneca’s Forxiga has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin in adults with type I diabetes.